<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    SI-BONE, Inc.

    SI-BONE, Inc.

    SI-BONE is a medical device company that has pioneered a proprietary minimally inv...

    SI-BONE is a medical device company that has pi...

    Filing Type:    PU
    IntriCon Corporation

    IntriCon Corporation

    For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...

    For more than 40 years, IntriCon has been meeti...

    Filing Type:    PU
    CashMD

    CashMD

    CashMD, a startup founded in 2017, brings patients and healthcare providers toget...

    CashMD, a startup founded in 2017, brings pati...

    Filing Type:    PR
    Novan, Inc.

    Novan, Inc.

    Novan, Inc. is a clinical development-stage biotechnology company focused on lever...

    Novan, Inc. is a clinical development-stage bio...

    Filing Type:    PU
    HTG Molecular Diagnostics, Inc.

    HTG Molecular Diagnostics, Inc.

    HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, an...

    HTG Molecular Diagnostics, Inc. ("HTG") is a pr...

    Filing Type:    PU
    Kazia Therapeutics Limited

    Kazia Therapeutics Limited

    Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...

    Kazia Therapeutics is an oncology-focused biote...

    Filing Type:    PU
    NantKwest, Inc.

    NantKwest, Inc.

    NantKwest is an innovative clinical-stage immunotherapy company focused on harness...

    NantKwest is an innovative clinical-stage immun...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Forty Seven, Inc.

    Forty Seven, Inc.

    Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...

    Forty Seven is a clinical-stage immuno-oncology...

    Filing Type:    PU
    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...

    20/20 GeneSystems, Inc. an early stage digital ...

    Fundraising Status:    SASBEC
    Filing Type:    RA
    Merrimack Pharmaceuticals, Inc.

    Merrimack Pharmaceuticals, Inc.

    Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...

    Merrimack is a biopharmaceutical company based ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.